Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2

Status

Terminated 5Completed 5Withdrawn 1Unknown 1

Sponsor Class

INDUSTRY 5OTHER 3

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Dermatologic 1CNS 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Tumor With Alterations of the FGF-R 1Melanoma 1Lung Neoplasms 1Glioblastoma 1Breast Neoplasms 1Acrocephalosyndactylia 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × INDUSTRY × infigratinib × Clear all
NCT02159066 2024-03-05

LOGIC-2

Pfizer

Phase 2 Completed
158 enrolled 40 charts
Dermatologic

Melanoma

NCT01928459 2020-12-09

Phase 1b Trial of BGJ398/BYL719 in Solid Tumors

Novartis

Phase 1 Completed
62 enrolled
Breast

Acrocephalosyndactylia, Breast Neoplasms

NCT01697605 2020-12-08

A Phase I Study of Oral BGJ398 in Asian Patients

Novartis

Phase 1 Completed
9 enrolled

Tumor With Alterations of the FGF-R

NCT01975701 2019-12-04

A Phase 2 Study of BGJ398 in Patients With Recurrent GBM

Novartis

Phase 2 Completed
26 enrolled 10 charts
CNS

Glioblastoma

NCT01004224 2019-10-04

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

Novartis

Phase 1 Completed
208 enrolled
GenitourinaryThoracic

Urinary Bladder Neoplasms, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡